Skip to main content
SpringerLink
Log in

Complications hépatiques du traitement des MICI

  • Chapter
Post’U FMC-HGE

  • 169 Accesses

Résumé

  • Connaître les principales classes de médicaments pouvant entraîner une atteinte hépatique;

  • Savoir prescrire le bilan nécessaire devant une suspicion d’hépatite médicamenteuse;

  • Savoir faire la part des choses entre une atteinte médicamenteuse et une hép atop athie liée aux MICI.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Davern TJ. Hépatotoxicity of immun-omodulating agents and the transplant situation. In Drug-induced liver disease, 2nd edition. Kaplowitz N and DeLeve L, eds. Informa Heathcare, New York 2007:662–81.

    Google Scholar 

  2. Larrey D. Hépatotoxicité des medicaments immunosupresseurs. Conduite diagnostique. Gastroenterol Clin Biol 2008;32:S194–S204.

    PubMed  CAS  Google Scholar 

  3. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease from steatosis to cirrhosis. Hepatology 2006;43:S99–S112.

    Article  PubMed  CAS  Google Scholar 

  4. Larrey D. Steatohépatite non alcoolique. Histoire naturelle et diagnostique. Gastroenterol Clin Biol 2003;27:793–8.

    PubMed  Google Scholar 

  5. Tinel M, Berson A, Pessayre D, Letteron P, Horsmans Y, larrey D. Pharmacogenetic of human erythrocyte thiopurine methyltransferase activity in a French population. Br J Clin pharmacol 1991;32:729–34.

    PubMed  CAS  Google Scholar 

  6. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002;22:27–42.

    Article  Google Scholar 

  7. Al Hadithy AF, deBoer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 2005; 37:282–97.

    Article  PubMed  CAS  Google Scholar 

  8. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL Pui CH et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608–14.

    PubMed  CAS  Google Scholar 

  9. Knowles SR, Gupta AK, Shear NH, Sauder D. Azathioprine hypersensitivity-like reactions-a case report and a review of the literature. Clin Exp Dermatol 1995;20:353–6.

    Article  PubMed  CAS  Google Scholar 

  10. Horsmans Y, Rahier J, Geubel AP. Reversible cholestasis with bile duct injury following azathioprine therapy. A case report. Liver 1991;11:89–93.

    PubMed  CAS  Google Scholar 

  11. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996;23:589–99.

    Article  Google Scholar 

  12. Ansari A, Elliot, Fong F, Arenas-Hernandez M, Rottenberg G, Portmann B, Lucas S, Marikani A, Sanderson J. Inflamm Bowel Dis 2008,14:1399–1405.

    Article  PubMed  Google Scholar 

  13. Gisbert JP, Luna M, Gonzalez-Lama Y, Pousa I, Velasco M, Moreno-Otero R, Maté J. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007;13:1106–14.

    Article  PubMed  Google Scholar 

  14. Reuben A. Methotrexate controversies. In Drug-induced liver disease, 2nd edition. Kaplowitz N and DeLeve L, eds. Informa Heathcare, New York 2007:683–705.

    Google Scholar 

  15. Hersh EM, Wong VG, Henderson ES, Freirich EJ. Hepatotoxic effects of methotrexate. Cancer 1996;19;600–6.

    Article  Google Scholar 

  16. Laharie D, Terrebonne E, Vergniol J, Chanteloup E, Chabrun E, Couzigou P, De Ledinghen V. Foie et méthotrexate. Gastroenterol Clin Biol 2008;32:134–42.

    Article  PubMed  CAS  Google Scholar 

  17. Laharie D, Zerbib F, Adhoute X, Boue-Lahorgue X, Foucher J, Castera L, Rullier A et al. Diagnosis of liver fibrosis by transient elastography (FibroScan) and noninvasive methods in Crohn’s disease patients treated with methotrexate. Aliment Pharmacol Ther 2006;23:1621–28.

    Article  PubMed  CAS  Google Scholar 

  18. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, D’Haens G, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006;55 (suppl11):16–35.

    Article  Google Scholar 

  19. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.

    Article  PubMed  CAS  Google Scholar 

  20. Maini R, StClair EW, Breedveld F, Furst D, Kalden J, Weisman M et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase in trial. ATTRACT Study Group. Lancet 1999;354:1932–9.

    Article  PubMed  CAS  Google Scholar 

  21. Larrey D. Liver toxicity of TNFα antagonists. Joint Bone Spine 2008; 75:636–8.

    Article  Google Scholar 

  22. Thiefin G, Morelet A, Heurgué A, Diebold MD, Eschard JP. Infliximabinduced hepatitis: absence of crosshepatotoxicity with etanercept. Revue de Rhumatologie, 2008 (sous presse)

    Google Scholar 

  23. Garcia Aparacio AM, Rey JR, Sanz AH, Alvarez JS. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 2007;26:811–3.

    Article  Google Scholar 

  24. Kooloos WM, DeJong DJ, Huizinga TWJ, Gushelaar HJ. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn’s disease. Drug Discov Today 2007;12:125–31.

    Article  PubMed  CAS  Google Scholar 

  25. Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS. Fatal massive hepatic necrosis: a probable hypersensitivity reaction to sulfasalazine. Am J Gastroenterol 1986;81:205–8.

    PubMed  CAS  Google Scholar 

  26. Marinos G, Riley J, Painter DM, McCaughan GW, Sulfasalazine-induced fulminant hepatic failure. J Clin Gastroenterol 1992;14:132–5.

    Article  PubMed  CAS  Google Scholar 

  27. Kassianides C, Nussenblatt R, Palestine AG, Mellow SD, Hoofnagle JH. Liver injury from cyclosporine A. Dig Dis Sci 1990;35:693–7.

    Article  PubMed  CAS  Google Scholar 

  28. Lorber MI, VanBuren CT, Flechner SM, Williams C, Kahan BD. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation 1987;43:35–40.

    Article  PubMed  CAS  Google Scholar 

  29. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004;53:1363–5.

    Article  PubMed  CAS  Google Scholar 

  30. Zekri AR, Mohamed WS, Samra MA, Sherif GM, El-Shehaby AM, El-Sayed MH. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol 2004;13:305–11.

    Article  PubMed  Google Scholar 

  31. Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG et al. Hepatitis C virus infection and bone marrowtransplantation: a cohort study with 10-year follow-up. Hepatology 1999;29:1893–9.

    Article  PubMed  CAS  Google Scholar 

  32. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Sem Liv Dis 2002;22:145–55.

    Article  CAS  Google Scholar 

  33. Pavy S, Constantin A, Pham T, Gossec L, Maillefert JF, Cantagrel A, Combe B et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006;73:388–95.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’Hépato-Gastroentérologie et Transplantation, Hôpital Saint-Eloi, 80, avenue Augustin Fliche, F-34295, Montpellier Cedex 5 et INSERN 632

    D. Larrey

Authors
  1. D. Larrey
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Michel Greff (Président FMC-HGE)

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Larrey, D. (2009). Complications hépatiques du traitement des MICI. In: Greff, M. (eds) Post’U FMC-HGE. Springer, Paris. https://doi.org/10.1007/978-2-287-99247-6_2

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-99247-6_2

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-99246-9

  • Online ISBN: 978-2-287-99247-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation